Prospective study of anti-PD-L1 antibody therapy in advanced non-small cell lung cancer patients who previously treated with anti-PD-1 antibody

Not Applicable

Recruiting

• Conditions: lung cancer

• Registration Number: JPRN-UMIN000033288
• Lead Sponsor: Japanese Red Cross Medical Center

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2018-07-05
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 30

Inclusion Criteria

Not provided

Exclusion Criteria

1. Patient whose administration of immune checkpoint inhibitor is contraindicated. 2. Patient with a history of cardiac function abnormality (acknowledging abnormality requiring treatment by electrocardiogram) or a history of myocardial infarction within 6 months before registration Patient with uncontrolled angina pectoris or heart failure. Patients with active duplicated cancers (excluding carcinoma within the carcinoma and duplicate carcinoma with no recurrence for more than 5 years). 3. Cases with complications of infection or patients suspected of having infection with fever 38 degrees Celsius or higher. 4. Pregnant women, patients who may be pregnant, breastfeeding patients. 5. Other patients judged inappropriate by the attending physician due to serious complications.

Study & Design

• Study Type: Observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Response rate

Secondary Outcome Measures

Name	Time	Method
Progression free survival: PFS Overall survival: OS Disease control rate: DCR Safety Predictors